Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint
Calliditas Therapeutics has reported that the Phase IIb TRANSFORM clinical trial of setanaxib, a NOX enzyme inhibitor, in people with…
Calliditas Therapeutics has reported that the Phase IIb TRANSFORM clinical trial of setanaxib, a NOX enzyme inhibitor, in people with…
Highlands Oncology and Paradigm have reported a 45% increase in clinical trial enrolment in Northwest Arkansas, US. This collaboration aims…
Eisai has adopted Medidata's Clinical Data Studio, which aims to transform and modernising the clinical trial efficiency and patient experience.…
Viridian Therapeutics has announced the completion of subject enrolment for its Phase III THRIVE-2 clinical trial of VRDN-001, aimed at…
The European Commission (EC) has awarded conditional marketing authorisation for Pfizer's DURVEQTIX (fidanacogene elaparvovec), a one-time gene therapy for use…
Autobahn Therapeutics has secured $100 in an oversubscribed Series C financing round for the commencement of two Phase II clinical…
Inimmune has dosed the first subject in its Phase I clinical trial of INI-4001, an immunotherapeutic agent designed for treating…
Sage Therapeutics and Biogen have disclosed topline results from the Phase II KINETIC 2 study, in which SAGE-324 (BIIB124) showed…
Pfizer has reported positive data from the Phase III AFFINE clinical trial of investigational gene therapy, giroctocogene fitelparvovec, to treat…
SpyBiotech has concluded subject enrolment in its Phase I clinical trial of SPYVLP01, a vaccine candidate aimed at human cytomegalovirus…